Evidence map›Paper›PMID 37431627›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.

Safiya A Zaloum, Callum H Wood, Pooja Tank, Mae Upcott, Nicola Vickaryous, Valerie Anderson, David Baker, Randy Chance, Nikos Evangelou, Katila George and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Safiya A ZaloumPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Callum H WoodDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Pooja TankPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Mae UpcottDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Nicola VickaryousPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Valerie AndersonDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
David BakerBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Randy ChanceBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK/Centre for Oral Immunobiology and Regenerative Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Nikos EvangelouClinical Neurology, Academic Unit of Mental Health and Clinical Neurosciences, University of Nottingham, Nottingham, UK.ORCID 0000-0003-2871-0672
Katila GeorgePreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Gavin GiovannoniPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK/Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK/Department of Neurology, Barts Health NHS Trust, London, UK.
Katharine E HardingDepartment of Neurology, Royal Gwent Hospital, Newport, UK.ORCID 0000-0001-6299-5582
Aimee HibbertClinical Neurology, Academic Unit of Mental Health and Clinical Neurosciences, University of Nottingham, Nottingham, UK.ORCID 0000-0003-0050-5669
Gillian IngramDepartment of Neurology, Morriston Hospital, Swansea, UK.
Stephen JollesImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK/School of Medicine, Cardiff University, Cardiff, UK.
Angray S KangBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK/Centre for Oral Immunobiology and Regenerative Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Samantha LovelessDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Stuart J MoatWales Newborn Screening Laboratory, Department of Medical Biochemistry, Immunology and Toxicology, University Hospital of Wales, Cardiff, UK/School of Medicine, Cardiff University, Cardiff, UK.
Aidan RichardsDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Neil P RobertsonDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK/Department of Neurology, University Hospital of Wales, Cardiff, UK.
Francesca RiosPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Klaus SchmiererBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK/Department of Neurology, Barts Health NHS Trust, London, UK.ORCID 0000-0002-9293-8893
Mark WillisDepartment of Neurology, University Hospital of Wales, Cardiff, UK.
Ruth DobsonPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK/Department of Neurology, Barts Health NHS Trust, London, UK.ORCID 0000-0002-2993-585X
Emma C TallantyreDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK/Department of Neurology, University Hospital of Wales, Cardiff, UK.ORCID 0000-0002-3760-6634
Queen Mary University of London · GBCardiff University · GBUniversity Hospital of Wales · GBUniversity of Nottingham · GBMorriston Hospital · GBRoyal Gwent Hospital · GB

Funding

Medical Research Council MR/L010305/1
6 · The paper itself

Abstract

backgroundPeople with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.

objectiveTo report COVID-19 rates in pwMS according to vaccine serology.

methodsPwMS with available (1) serology 2-12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included. Logistic regression was performed to examine whether seroconversion following vaccination predicted risk of subsequent COVID-19 infection after adjusting for potential confounders. Rates of severe COVID-19 (requiring hospitalisation) were also calculated.

resultsA total of 647 pwMS were included (mean age 48 years, 500 (77%) female, median Expanded Disability Status Scale (EDSS) 3.5% and 524 (81%) exposed to DMT at the time of vaccine 1). Overall, 472 out of 588 (73%) were seropositive after vaccines 1 and 2 and 222 out of 305 (73%) after vaccine 3. Seronegative status after vaccine 2 was associated with significantly higher odds of subsequent COVID-19 infection (odds ratio (OR): 2.35, 95% confidence interval (CI): 1.34-4.12,

conclusionAttenuated humoral response to initial COVID-19 vaccination predicts increased risk of COVID-19 in pwMS, but overall low rates of severe COVID-19 were seen.

Indexed as

COVID-19COVID-19 VaccinesMultiple SclerosisFemaleHospitalizationHumansMaleMiddle AgedVaccinationCOVID-19 VaccinesCOVID-19disease-modifying therapies (DMTs)immune responseMultiple sclerosis (MS)vaccination

Identifiers

PMID37431627
PMCPMC10333979
OpenAlexW4383872939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.